EEG findings in CAR T-cell therapy-related encephalopathy.
作者信息
Herlopian Aline, Dietrich Jorg, Abramson Jeremy S, Cole Andrew J, Westover Michael B
机构信息
From the Yale Comprehensive Epilepsy Center (A.H.), Yale University/Yale New Haven Hospital, New Haven, CT; and Massachusetts General Hospital (J.D., J.S.A., A.J.C., M.B.W.), Boston.
出版信息
Neurology. 2018 Jul 31;91(5):227-229. doi: 10.1212/WNL.0000000000005910. Epub 2018 Jun 29.
Abstract
摘要
相似文献
1
EEG findings in CAR T-cell therapy-related encephalopathy.嵌合抗原受体T细胞疗法相关脑病的脑电图检查结果
Neurology. 2018 Jul 31;91(5):227-229. doi: 10.1212/WNL.0000000000005910. Epub 2018 Jun 29.
2
Beginning the CAR T cell therapy revolution in the US and EU.开启美国和欧盟的嵌合抗原受体T细胞（CAR T）疗法革命。
Curr Res Transl Med. 2018 May;66(2):62-64. doi: 10.1016/j.retram.2018.03.004. Epub 2018 Apr 12.
3
Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy.COVID-19 和 CAR-T 治疗中的大脑功能障碍：细胞因子风暴相关脑病。
Ann Clin Transl Neurol. 2021 Apr;8(4):968-979. doi: 10.1002/acn3.51348. Epub 2021 Mar 29.
4
CAR T cells - what have we learnt?嵌合抗原受体T细胞——我们学到了什么？
Nat Rev Clin Oncol. 2017 Dec 15;15(1):1. doi: 10.1038/nrclinonc.2017.196.
5
Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.免疫疗法：替沙格赛定 - 首个获批的嵌合抗原受体T细胞疗法：对支付方和政策制定者的影响
Nat Rev Clin Oncol. 2018 Jan;15(1):11-12. doi: 10.1038/nrclinonc.2017.156. Epub 2017 Oct 4.
6
Advances in Universal CAR-T Cell Therapy.通用 CAR-T 细胞治疗的进展。
Front Immunol. 2021 Oct 6;12:744823. doi: 10.3389/fimmu.2021.744823. eCollection 2021.
7
CAR T-cells: A John von Neumann legacy?嵌合抗原受体T细胞：约翰·冯·诺依曼的遗产？
Curr Res Transl Med. 2018 May;66(2):35-36. doi: 10.1016/j.retram.2018.04.002. Epub 2018 Apr 21.
8
Next generation T-cell therapy for genitourinary malignancies, part A: Introduction and current state of the art.用于泌尿生殖系统恶性肿瘤的新一代T细胞疗法，A部分：引言与当前技术水平
Cancer Treat Res Commun. 2018;17:8-12. doi: 10.1016/j.ctarc.2018.08.001. Epub 2018 Aug 22.
9
Celyad's novel CAR T-cell therapy for solid malignancies.西利亚德公司用于实体瘤的新型嵌合抗原受体 T 细胞疗法。
Curr Res Transl Med. 2018 May;66(2):53-56. doi: 10.1016/j.retram.2018.03.001. Epub 2018 Apr 4.
10
Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.嵌合抗原受体修饰 T 细胞疗法的临床前模型。
Hum Gene Ther. 2018 May;29(5):534-546. doi: 10.1089/hum.2017.243. Epub 2018 Mar 14.
引用本文的文献
1
EEG as a predictive biomarker of neurotoxicity in anti-CD19 CAR T-cell therapy.脑电图作为抗CD19嵌合抗原受体T细胞疗法中神经毒性的预测生物标志物。
J Neurol. 2025 Apr 25;272(5):360. doi: 10.1007/s00415-025-13102-3.
2
Mechanisms and management of CAR T toxicity.嵌合抗原受体T细胞毒性的机制与管理
Front Oncol. 2024 May 21;14:1396490. doi: 10.3389/fonc.2024.1396490. eCollection 2024.
3
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy.抗CD19嵌合抗原受体T细胞疗法中预防性抗癫痫药物的初始治疗与抢先治疗对比
Neurol Sci. 2024 Aug;45(8):4007-4014. doi: 10.1007/s10072-024-07481-0. Epub 2024 Mar 21.
4
Automated detection of immune effector cell-associated neurotoxicity syndrome via quantitative EEG.通过定量脑电图自动检测免疫效应细胞相关神经毒性综合征。
Ann Clin Transl Neurol. 2023 Oct;10(10):1776-1789. doi: 10.1002/acn3.51866. Epub 2023 Aug 6.
5
Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion.前额间歇性节律性德尔塔活动是 CAR T 细胞输注后神经毒性的有用诊断工具。
Neurol Neuroimmunol Neuroinflamm. 2023 Apr 14;10(4). doi: 10.1212/NXI.0000000000200111. Print 2023 Jul.
6
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.嵌合抗原受体 T 细胞疗法治疗实体瘤的现状：机制、研究进展、挑战和对策。
Front Immunol. 2023 Mar 20;14:1113882. doi: 10.3389/fimmu.2023.1113882. eCollection 2023.
7
EEG-based grading of immune effector cell-associated neurotoxicity syndrome.基于脑电图的免疫效应细胞相关神经毒性综合征分级。
Sci Rep. 2022 Nov 21;12(1):20011. doi: 10.1038/s41598-022-24010-1.
8
Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).免疫效应细胞相关神经毒性综合征（ICANS）中的急性癫痫发作和癫痫持续状态。
Blood Cancer J. 2022 Apr 13;12(4):62. doi: 10.1038/s41408-022-00657-x.
9
Brain capillary obstruction during neurotoxicity in a mouse model of anti-CD19 chimeric antigen receptor T-cell therapy.抗CD19嵌合抗原受体T细胞疗法小鼠模型中神经毒性期间的脑毛细血管阻塞
Brain Commun. 2021 Dec 31;4(1):fcab309. doi: 10.1093/braincomms/fcab309. eCollection 2022.
10
Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy.嵌合抗原受体（CAR）-T细胞疗法背景下的复发性癫痫持续状态
Neurohospitalist. 2022 Jan;12(1):74-79. doi: 10.1177/19418744211000980. Epub 2021 Mar 11.
本文引用的文献
1
New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.新药，新毒性：癌症现代靶向治疗和免疫治疗的严重副作用及其管理
Crit Care. 2017 Apr 14;21(1):89. doi: 10.1186/s13054-017-1678-1.
2
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.来那度胺增强嵌合抗原受体修饰的T细胞的抗肿瘤功能。
Oncoimmunology. 2015 Dec 3;5(4):e1115940. doi: 10.1080/2162402X.2015.1115940. eCollection 2016 Apr.
3
Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.社区肿瘤学家的嵌合抗原受体T细胞疗法
Oncologist. 2016 May;21(5):608-17. doi: 10.1634/theoncologist.2015-0421. Epub 2016 Mar 23.
4
Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.来那度胺通过增强免疫突触来增强嵌合抗原受体T细胞针对表皮生长因子受体变异体III的功能。
Cancer Gene Ther. 2015 Oct;22(10):487-95. doi: 10.1038/cgt.2015.47. Epub 2015 Oct 9.
5
Generalized periodic discharges in the critically ill: a case-control study of 200 patients.危重病患者的广义周期性放电：200 例患者的病例对照研究。
Neurology. 2012 Nov 6;79(19):1951-60. doi: 10.1212/WNL.0b013e3182735cd7. Epub 2012 Oct 3.
Zotero 插件